Skip to content
ClinCalc Pro
Menu
Topical haemorrhoidal preparation

Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, Peru balsam and zinc oxide

Brand names: Anusol HC, Proctosedyl

Used in: Anaphylaxis & Allergy

This is a compound topical preparation for the symptomatic relief of haemorrhoids and perianal irritation, combining benzyl benzoate, bismuth salts, hydrocortisone acetate, Peru balsam and zinc oxide.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It combines a mild topical corticosteroid (hydrocortisone acetate) to reduce inflammation with astringent and soothing/protectant components (bismuth salts, zinc oxide) and Peru balsam.

Prescribing in practice

  • Because it contains a corticosteroid, limit to short-term use, as prolonged perianal application can cause skin thinning; exclude infection first.
  • Peru balsam and other constituents may cause local sensitisation, so discontinue if irritation or an allergic reaction develops.
  • It is intended for short courses of symptomatic relief rather than ongoing treatment.

Monitoring

No laboratory monitoring is required; review symptoms and stop if there is no improvement or if local reactions occur.

Counselling the patient

  • Use for short periods only and seek review if symptoms persist, recur or worsen.
  • Stop and seek advice if rectal bleeding occurs or the area becomes more irritated.
  • Attention to fibre, fluids and avoiding straining helps the underlying problem.

Evidence & guidelines

Compound corticosteroid-containing haemorrhoidal preparations are recommended for short-term symptomatic relief in line with standard UK practice.

Reference: NICE CKS Haemorrhoids; ACPGBI; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.